{"id":"https://openalex.org/W7136138259","doi":"https://doi.org/10.1158/1078-0432.31744725","title":"Figure 3 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer","display_name":"Figure 3 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer","publication_year":2026,"publication_date":"2026-03-16","ids":{"openalex":"https://openalex.org/W7136138259","doi":"https://doi.org/10.1158/1078-0432.31744725"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.31744725","doi":"https://doi.org/10.1158/1078-0432.31744725","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.31744725","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.31744725","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042743608","display_name":"Komal L. Jhaveri","orcid":"https://orcid.org/0000-0003-0472-1254","observed_orcids":["https://orcid.org/0000-0003-0472-1254"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Komal Jhaveri","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0472-1254","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010278367","display_name":"Sherene Loi","orcid":"https://orcid.org/0000-0001-6137-9171","observed_orcids":["https://orcid.org/0000-0001-6137-9171"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sherene Loi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6137-9171","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003060935","display_name":"Erika Paige Hamilton","orcid":"https://orcid.org/0000-0002-1911-0336","observed_orcids":["https://orcid.org/0000-0002-1911-0336"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erika Hamilton","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1911-0336","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5122014418","display_name":"Peter Schmid","orcid":"https://orcid.org/0000-0001-9817-5228","observed_orcids":["https://orcid.org/0000-0001-9817-5228"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Schmid","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9817-5228","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013557141","display_name":"Carey K. Anders","orcid":"https://orcid.org/0000-0001-9165-4074","observed_orcids":["https://orcid.org/0000-0001-9165-4074"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carey K. Anders","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9165-4074","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036420234","display_name":"Laura Testa","orcid":"https://orcid.org/0000-0001-6080-7429","observed_orcids":["https://orcid.org/0000-0001-6080-7429"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laura Testa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6080-7429","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5129551437","display_name":"Hans Wildiers","orcid":"https://orcid.org/0000-0001-8990-7837","observed_orcids":["https://orcid.org/0000-0001-8990-7837"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hans Wildiers","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8990-7837","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5129490845","display_name":"Ling-Ming Tseng","orcid":"https://orcid.org/0000-0002-4648-6646","observed_orcids":["https://orcid.org/0000-0002-4648-6646"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ling-Ming Tseng","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4648-6646","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009846821","display_name":"Yen\u2010Shen Lu","orcid":"https://orcid.org/0000-0001-7461-1291","observed_orcids":["https://orcid.org/0000-0001-7461-1291"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yen-Shen Lu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7461-1291","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101445353","display_name":"Yeon Hee Park","orcid":"https://orcid.org/0000-0003-4156-9212","observed_orcids":["https://orcid.org/0000-0003-4156-9212"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yeon Hee Park","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4156-9212","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069050806","display_name":"Seock\u2010Ah Im","orcid":"https://orcid.org/0000-0002-5396-6533","observed_orcids":["https://orcid.org/0000-0002-5396-6533"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Seock-Ah Im","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5396-6533","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5129619639","display_name":"Shin-Cheh Chen","orcid":"https://orcid.org/0000-0002-0177-0045","observed_orcids":["https://orcid.org/0000-0002-0177-0045"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shin-Cheh Chen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0177-0045","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061388899","display_name":"Robyn R. Young","orcid":"https://orcid.org/0000-0003-4466-8240","observed_orcids":["https://orcid.org/0000-0003-4466-8240"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robyn R. Young","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4466-8240","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108681364","display_name":"Caron Lloyd","orcid":"https://orcid.org/0009-0003-0259-8042","observed_orcids":["https://orcid.org/0009-0003-0259-8042"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Caron Lloyd","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0003-0259-8042","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052652518","display_name":"Magdalena Wrona","orcid":"https://orcid.org/0000-0003-1095-4660","observed_orcids":["https://orcid.org/0000-0003-1095-4660"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Magdalena Wrona","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1095-4660","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126215210","display_name":"Cuihong Zhang","orcid":"https://orcid.org/0000-0001-6816-1327","observed_orcids":["https://orcid.org/0000-0001-6816-1327"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cuihong Zhang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6816-1327","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046909219","display_name":"Danielle K. Carroll","orcid":"https://orcid.org/0009-0002-0297-4119","observed_orcids":["https://orcid.org/0009-0002-0297-4119"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danielle Carroll","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-0297-4119","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5001814176","display_name":"Fabrice Andr\u00e9","orcid":"https://orcid.org/0000-0001-5795-8357","observed_orcids":["https://orcid.org/0000-0001-5795-8357","https://orcid.org/0000-0002-6272-6048"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fabrice Andr\u00e9","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5795-8357","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.92330002784729,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.92330002784729,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.05779999867081642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab-deruxtecan","display_name":"trastuzumab deruxtecan","score":0.9990000128746033},{"id":"https://openalex.org/keywords/her2-low-metastatic-breast-cancer","display_name":"HER2-low metastatic breast cancer","score":0.9629999995231628},{"id":"https://openalex.org/keywords/anastrozole","display_name":"anastrozole","score":0.9710000157356262},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":1.0},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6119999885559082},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.9480000138282776},{"id":"https://openalex.org/keywords/combination-endocrine-therapy","display_name":"combination endocrine therapy","score":0.550000011920929}],"concepts":[{"id":"https://openalex.org/C2776215463","wikidata":"https://www.wikidata.org/wiki/Q419143","display_name":"Anastrozole","level":5,"score":0.857200026512146},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8317000269889832},{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.7903000116348267},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.7870000004768372},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.7864000201225281},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6363000273704529},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6291000247001648},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.43549999594688416},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3625999987125397},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3409000039100647},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3084000051021576},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.29190000891685486},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.28940001130104065},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.2766000032424927},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2632000148296356},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.2605000138282776},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.25920000672340393}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.31744725","doi":"https://doi.org/10.1158/1078-0432.31744725","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.31744725","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.31744725","doi":"https://doi.org/10.1158/1078-0432.31744725","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.31744725","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7136171818","https://openalex.org/W4396587448","https://openalex.org/W7119502508","https://openalex.org/W7136972212","https://openalex.org/W7137236624","https://openalex.org/W7136463288","https://openalex.org/W7136131756","https://openalex.org/W7136606868","https://openalex.org/W4281887786","https://openalex.org/W3132317397"],"abstract_inverted_index":{"Best":[0],"percentage":[1],"change":[2],"in":[3],"target":[4],"lesions":[5],"from":[6],"baseline":[7],"for":[8],"(A)":[9],"T-DXd":[10,15],"+":[11,16,47,58],"anastrozole":[12,48],"and":[13],"(B)":[14],"fulvestrant.":[17],"1L,":[18],"first-line;":[19],"2L,":[20],"second-line;":[21],"IM,":[22],"intramuscularly;":[23],"IV,":[24],"intravenously;":[25],"OD,":[26],"once":[27],"daily;":[28],"PO,":[29],"orally;":[30],"Q3W,":[31],"every":[32,36],"3":[33],"weeks;":[34,38],"Q4W,":[35],"4":[37],"T-DXd,":[39],"trastuzumab":[40],"deruxtecan.":[41],"aT-DXd":[42],"5.4":[43,54],"mg/kg":[44,55],"IV":[45,56],"Q3W":[46,57],"1":[49],"mg":[50,61],"PO":[51],"OD.":[52],"bT-DXd":[53],"fulvestrant":[59],"500":[60],"IM":[62],"Q4W":[63],"with":[64],"500-mg":[65],"loading":[66],"dose":[67],"on":[68],"Day":[69],"15":[70],"of":[71],"Cycle":[72],"1.":[73]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2026-03-17T00:00:00"}